Faculty, Staff and Student Publications

Language

English

Publication Date

7-1-2023

Journal

Medicinal Research Reviews

DOI

10.1002/med.21940

PMID

36905090

PMCID

PMC10247541

PubMedCentral® Posted Date

7-1-2024

PubMedCentral® Full Text Version

Author MSS

Abstract

Since time immemorial human beings have constantly been fighting against viral infections. The ongoing and devastating coronavirus disease 2019 pandemic represents one of the most severe and most significant public health emergencies in human history, highlighting an urgent need to develop broad-spectrum antiviral agents. Salicylamide (2-hydroxybenzamide) derivatives, represented by niclosamide and nitazoxanide, inhibit the replication of a broad range of RNA and DNA viruses such as flavivirus, influenza A virus, and coronavirus. Moreover, nitazoxanide was effective in clinical trials against different viral infections including diarrhea caused by rotavirus and norovirus, uncomplicated influenza A and B, hepatitis B, and hepatitis C. In this review, we summarize the broad antiviral activities of salicylamide derivatives, the clinical progress, and the potential targets or mechanisms against different viral infections and highlight their therapeutic potential in combating the circulating and emerging viral infections in the future.

Keywords

Humans, COVID-19, Thiazoles, Nitro Compounds, Antiviral Agents, Salicylamides, Virus Replication, salicylamide derivatives, infectious diseases, nitazoxanide, niclosamide, broad-spectrum antiviral agents

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.